CONFIDeNT: UK Trial of Percutaneous Tibial Nerve Stimulation in Patients With Faecal Incontinence

Sponsor
Queen Mary University of London (Other)
Overall Status
Completed
CT.gov ID
NCT02349334
Collaborator
(none)
227
2
32

Study Details

Study Description

Brief Summary

Faecal incontinence occurs when a person passes faeces (stools) without the usual control. It is a distressing condition that is actually very common although under-reported because of embarrassment. Milder symptoms may be managed by treatments such as dietary change, drugs and bowel retraining, but many patients still resort to surgery to improve symptoms. Although several operations exist to treat incontinence e.g. those aiming to repair damaged anal sphincter muscles, it is now clear that these often have poor results.

Two relatively new treatments called sacral nerve stimulation (SNS) and percutaneous tibial nerve stimulation (PTNS) involve sending pulses of electricity to the nerves controlling the bowel and muscles of the anus (anal sphincter).

SNS does this by inserting electrodes in the lower back just above the tailbone and connecting them to an implanted electrical stimulator which is buried in the buttock and acts a bit like a heart pacemaker. SNS is a relatively well-established treatment in specialist centres, which has been used for over 10 years. It has been shown in studies to be successful for faecal incontinence achieving some improvement in at least three quarters of patients. In Europe, this procedure is fast becoming first treatment offered when non-surgical treatments fail. Nevertheless, SNS is not a miracle cure for all, requiring 2 operations, with potential complications and expensive equipment (> £10,000 approx).

PTNS is a newer treatment, which involves electrically stimulating a nerve at the ankle, using a very small needle, as an outpatient (a bit like acupuncture). This sends signals back to the spine region to try and improve symptoms of faecal incontinence. Since this is a newer treatment, fewer studies have been performed to quantify how successful it is, but early results of PTNS suggest that it may be as good as SNS. If this is true, this is very important because it is much less invasive and considerably cheaper than SNS (equipment £500 per patient).

This project will for the first time determine how effective PTNS is in the treatment of patients with faecal incontinence, by comparing it to sham (fake stimulation). This study is a properly designed clinical trial of 212 patients in at least 14 UK Specialist Centres.. The results of this trial will lead to direct benefits for patients and the NHS.

Condition or Disease Intervention/Treatment Phase
  • Device: Percutaneous Tibial Nerve Stimulation
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
227 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
CONtrol of Faecal Incontinence Using Distal NeuromodulaTion (CONFIDeNT)
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Feb 1, 2014
Actual Study Completion Date :
Sep 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: Sham electrical stimulation

Sham electrical stimulation to forefoot by TENS

Device: Percutaneous Tibial Nerve Stimulation

Active Comparator: Percutaneous tibial nerve stimulation

Active PTNS via Urgent PC Neuromodulation device, Uroplasty

Device: Percutaneous Tibial Nerve Stimulation

Outcome Measures

Primary Outcome Measures

  1. Primary outcome: Binary - success or failure based on % patients achieving > or = 50% reduction in faecal incontinence episodes [3 months]

    From 2 weekly bowel diaries before and after treatment

Secondary Outcome Measures

  1. Reduction in faecal incontinence episodes [3 months]

  2. Proportion of patients achieving >25%, >75% and 100% reduction in faecal incotinence episodes [3 months]

  3. Reduction in Cleveland Clinic Constipation Score [3 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Faecal incontinence sufficiently severe enough to warrant intervention

  • Failure of appropriate conservative therapies

  • Age ≥ 18 years

Exclusion Criteria:
  • Inability to provide informed consent for the research study

  • Inability to fill in the detailed bowel diaries required for outcome assessments (this will exclude participants who do not speak / read English)*

  • Neurological diseases, such as diabetic neuropathy, multiple sclerosis and Parkinson's disease (any participant with painful peripheral neuropathy)

  • Anatomical limitations that would prevent successful placement of needle electrode

  • Other medical conditions precluding stimulation: e.g. bleeding disorders, certain cardiac pacemakers, peripheral vascular disease or ulcer, lower leg cellulitis

  • Congenital anorectal anomalies or absence of native rectum due to surgery

  • A cloacal defect

  • Present evidence of external full thickness rectal prolapse

  • Previous rectal surgery (rectopexy / resection) done < 12 months ago (24 months for cancer),

  • Stoma in situ

  • Chronic bowel diseases such as inflammatory bowel disease leading to chronic uncontrolled diarrhoea

  • Pregnancy or intention to become pregnant

  • Previous experience of SNS or PTNS

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Queen Mary University of London

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Queen Mary University of London
ClinicalTrials.gov Identifier:
NCT02349334
Other Study ID Numbers:
  • 34825
  • 09/104/16
First Posted:
Jan 28, 2015
Last Update Posted:
Jan 28, 2015
Last Verified:
Jan 1, 2015
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 28, 2015